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The European Centre for Disease Prevention and 
Control (ECDC) initiated a project on the molecular 
surveillance of multi- and extensively drug-resist-
ant tuberculosis (MDR-/XDR-TB) transmission in the 
European Union (EU) in the period from 2009 to 2011. In 
total, 2,092 variable number of tandem repeat (VNTR) 
patterns of MDR-/XDR-TB Mycobacterium tuberculosis 
isolates were collected, originating from 24 different 
countries in the period 2003 to 2011. Of the collected 
VNTR patterns, 45% (n=941) could be assigned to one 
of the 79 European multiple-country molecular finger-
print clusters and 50% of those (n=470) belonged to 
one extremely large cluster caused by Beijing strains 
of one genotype. We conclude that international trans-
mission of MDR-/XDR-TB plays an important role in 
the EU, especially in the eastern part, and is signifi-
cantly related to the spread of one strain or clone of 
the Beijing genotype. Implementation of international 
cluster investigation in EU countries should reveal 
underlying factors of transmission, and show how TB 
control can be improved regarding case finding, con-
tact tracing, infection control and treatment in order to 
prevent further spread of MDR-/XDR-TB in the EU.
Introduction
Molecular surveillance of multi- and extensively drug-
resistant tuberculosis (MDR-/XDR-TB) in the European 
Union (EU) on basis of IS6110 restriction fragment 
length polymorphism (RFLP) typing detected large 
molecular clusters of MDR-/XDR-TB cases across EU 
countries in the period 2003 to 2007 [1]. It also iden-
tified possible transmission patterns and risk factors 
for MDR-TB and XDR-TB, such as country of origin and 
infection with the Beijing genotype [2]. Following up 
on these findings, the European Centre for Disease 
Prevention and Control (ECDC) initiated a molecular 
surveillance project on MDR-/XDR-TB in the EU from 
2009 to 2012 which was built on the existing TB net-
work previously funded by the European Commission. 
This new project, carried out by the National Institute 
for Public Health and the Environment (RIVM) on behalf 
of the ECDC, aimed at achieving a higher coverage 
by expanding molecular typing to countries in the EU 
where this was not yet the practice. For this purpose, 
the 24-locus mycobacterial interspersed repetitive unit 
variable number of tandem repeat (MIRU-VNTR) typing 
method was selected as the main DNA fingerprinting 
methodology [3]. This method has become the inter-
national gold standard for typing of Mycobacterium 
tuberculosis isolates and offers important advantages 
over IS6110 RFLP typing, while its discriminatory power 
equals that of IS6110 [3,4]. Firstly, VNTR typing is 
easier to perform than RFLP typing and can be imple-
mented more efficiently in countries that do not yet 
perform molecular typing. Secondly, it is based on DNA 
amplification, which abolishes the need for culture of 
M. tuberculosis and has a shorter laboratory turn-
around time. Moreover, this approach uses low quan-
tities of DNA and allows exchange of (non-viable) 
mycobacterial culture material by regular mail. Finally, 
the results of VNTR typing are in a simple format, which 
facilitates efficient exchange of typing information and 
inter-laboratory comparison. In principle, this intro-
duces more real-time typing and rapid feedback on 
molecular clustering to identify newly emerging MDR-/
XDR-TB strains.
This paper describes the major findings of the ECDC/
RIVM project regarding the detection of international 
clusters, the molecular typing coverage of MDR-/
XDR-TB cases, the conclusions drawn from molecular 
analysis and recommendations for the future develop-
ment of molecular surveillance of MDR-/XDR-TB in the 
EU. 
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Methods
Project design
Molecular typing data of MDR-/XDR-TB cases from 
EU countries were collected in the period from 2009 
to 2011 by the RIVM in Bilthoven, the Netherlands. 
Furthermore, retrospective typing of isolates collected 
from patients in the period from 2003 to 2008 and 
real-time typing of isolates collected from patients 
from 2009 to the end of 2011 were included. The RIVM 
reported clustering of MDR-/XDR-TB cases to the ECDC 
on a regular basis. In addition, the implementation, 
standardisation and quality control of VNTR typing in 
all participating countries was facilitated by ad hoc 
email contact, on-site training, by project meetings 
and workshops, and also by the introduction of a profi-
ciency testing programme for VNTR typing [5]. The col-
lection of samples did not follow a rational selection 
but was driven by the specific situation in the different 
participating countries.
Participants in the project
This molecular surveillance project was designed 
for all EU, European Economic Area (EEA), and EU 
Table 1
Culture-confirmed multi- and extensively drug-resistant tuberculosis cases reported to the TESSy system, and coverage in 
the molecular surveillance project, by country, 2003–2011 (n=16,858)
Country of 
isolation
Year of isolation Total 
reported to 
ECDC 
2003–11
Total  with 
molecular 
surveillance 
data
2003–11
Coverage
2003 2004 2005 2006 2007 2008 2009 2010 2011
Austria 12 19 13 10 9 15 22 15 19 134 NR NA
Belgium 9 12 11 18 14 21 10 19 15 129 30 23%
Bulgaria 44 47 47 53 76 31 43 56 55 452 141 31%
Croatia 8 3 7 3 3 4 7 NR 2 37 56 151%a
Cyprus 0 0 1 0 3 1 4 0 1 10 1 10%
Czech Republic 2 6 13 12 8 11 8 9 7 76 37 49%
Denmark 0 0 5 3 2 0 2 2 3 17 15 88%
Estonia 106 90 78 55 82 73 85 63 78 710 557 78%
Finland 3 0 2 2 2 1 6 6 5 27 20 74%
France 25 26 24 30 20 27 30 23 40 245 87 36%
Germany 91 98 103 82 66 49 62 48 56 655 62 9%
United Kingdom 52 47 40 51 56 53 60 60 81 500 120 24%
Greece 22 16 12 13 14 0 14 0 5 96 48 50%
Hungary 20 11 17 14 12 13 18 19 7 131 36 27%
Ireland 1 2 3 4 7 2 1 2 3 25 18 72%
Italy 42 24 22 28 56 71 82 87 81 493 248 50%
Latvia 174 195 161 142 99 128 131 87 95 1,212 30 2%
Liechtenstein NR NR NR NR NR NR NR NR NR 0 NR NA
Lithuania 312 318 338 332 314 276 322 310 296 2,818 73 3%
Luxembourg 1 1 0 0 0 0 0 0 2 4 NR NA
Norway 3 4 3 3 3 4 8 8 4 40 28 70%
Poland 92 51 46 32 22 19 21 30 41 354 NR NA
Portugal 23 35 31 22 34 32 24 19 22 242 NR NA
Romania 585 810 849 673 673 792 624 502 530 6,038 NR NA
Slovakia 6 1 8 7 7 4 1 1 3 38 13 34%
Slovenia 1 0 1 1 0 2 1 0 0 6 6 100%
Spain 47 59 80 50 59 76 56 49 41 517 242 47%
Sweden 7 6 4 3 15 11 13 18 17 94 75 80%
The Netherlands 8 3 3 5 3 13 20 11 15 81 92 114%a
Turkey 0 0 191 249 240 263 222 250 262 1,677 20 1%
Total 16,858 2,055 12%
NA: not applicable; NR: not reported; ECDC: European Centre for Disease Prevention and Control; TESSy: The European Surveillance System at 
ECDC.
a More than 100% coverage is the result of incomplete culture data collection by the ECDC.
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candidate countries. The countries with national ref-
erence laboratories participating in the project were: 
Austria, Belgium, Bulgaria, Croatia, Cyprus, the Czech 
Republic, Denmark, Estonia, Finland, France, Germany, 
Greece, Hungary, Ireland, Italy, Latvia, Liechtenstein, 
Lithuania, Luxembourg, the Netherlands, Norway, 
Poland, Portugal, Romania, Slovakia, Slovenia, Spain, 
Sweden, Turkey and the United Kingdom.
MIRU-VNTR typing
The standard for typing M. tuberculosis complex strains 
was the method described by Supply et al. in 2006 [3]. 
The RIVM offered MIRU-VNTR typing to the countries 
that were not able to perform the technique locally or 
were not performing it for other reasons. Specifically, 
the RIVM performed VNTR typing for Cyprus, the Czech 
Republic, Estonia, Greece, Hungary, Latvia, Norway, 
Slovakia and Spain, and partial typing for Finland and 
Lithuania.
Drug susceptibility testing
Phenotypic drug susceptibility testing (DST) was per-
formed by the TB reference laboratories participat-
ing in the project. All M. tuberculosis isolates were 
tested at least for resistance to the first-line antibiotics 
rifampicin and isoniazid, and part of the strains were 
also tested for resistance against second-line anti-
biotics such as fluoroquinolones and the injectable 
drugs (capreomycin and aminoglycosides), accord-
ing to national guidelines for DST. All participating 
laboratories were members of the European Reference 
Laboratory Network (ERLN)-TB and had their own 
national accreditation.
Molecular assessment of susceptibility by 
MTBDRplus assay
 We selected for molecular assessment strains that 
belonged to the largest European MDR-TB cluster, 
with a view of including a wide spread of country and 
year of isolation. For selected strains, the GenoType 
MTBDRplus reverse line blot method (HAIN Lifescience, 
Nehren, Germany) [6] was applied to detect mutations 
in the rpoB gene associated with rifampicin resistance 
and mutations in the katG gene and the inhA gene 
associated with isoniazid resistance. 
Coverage
Based on the tested samples from the period 2003 
to 2011, we defined the coverage of molecular finger-
printing of MDR-/XDR-TB as the percentage of MDR-/
XDR-TB isolates included in the molecular surveil-
lance project among the total number of MDR-/XDR-TB 
cases officially reported to the ECDC for the same 
period. The ECDC published the surveillance results in 
The European Surveillance System (TESSy) and in the 
annual surveillance reports. 
Clustering
A European cluster was defined as two or more MDR-/
XDR-TB strains with identical 24-locus VNTR typing 
patterns, isolated in at least two different countries. 
Results for 15-locus VNTR typing and VNTR patterns for 
which one or more loci were missing were also included 
in the cluster analysis.
Beijing genotype identification
The Beijing genotype was identified by the specific 
Beijing branch of the dendrogram with a similarity per-
centage of 24-locus VNTR typing of at least 60%. The 
Beijing branch was determined by 656 isolates con-
firmed as the Beijing genotype based on spoligotyp-
ing. The non-Beijing branches were confirmed as such 
by spoligotyping of 201 isolates.
Results
Coverage
The countries participating in the project reported 
16,858 MDR-/XDR-TB cases to the ECDC for the period 
2003 to 2011. The total number of MDR-/XDR-TB iso-
lates collected in that period for which VNTR typing 
data were available amounted to 2,055. Therefore, the 
coverage of the molecular surveillance for the period 
2003 to 2011 was 12%. Six countries reported no 
molecular typing results at all; excluding these coun-
tries, the coverage was 20%. The coverage differed 
significantly by country and year (Table 1).  
Typing
We collected 2,092 VNTR patterns, originating from 
2,055 MDR-/XDR-TB patients sampled between 2003 
and 2011 in 24 different countries (Figure 1). There 
were more VNTR patterns than isolates because dou-
ble alleles were detected in the VNTR patterns of 37 
Figure 1
Number of VNTR patterns of multi- and extensively drug-
resistant Mycobacterium tuberculosis isolates included in 
the molecular surveillance project, by country of isolation, 
sampled 2003–2011 (n=2,092)
VNTR: variable number of tandem repeat.
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isolates that were included in the project database as 
separate patterns. For 53% (n=1,093) of the included 
isolates, the typing results were produced by the ref-
erence laboratory of the country of isolation, and for 
47% (n=962) the molecular typing was performed at 
the RIVM. 
The number of isolates included per year is depicted in 
Figure 2; 2009 was the year with the highest number of 
isolates included (n=415). The sex was known for 69% 
(n=1,428) of the cases whose isolates were typed: 70% 
(n=999) of the MDR-/XDR-TB cases were male and 30% 
(n=429) female. The age at the time of TB diagnosis 
was available for 68% (n=1,402) of the MDR-/XDR-TB 
cases included in this study: their mean age was 40 
years (range: 1–88 years).
Clustering
Comparison of the 2,092 VNTR patterns included in the 
project resulted in the detection of 79 European clus-
ters. The cluster sizes varied from two to 470 cases per 
cluster (Figure 3). In total, 45% (n=941) of all the col-
lected VNTR patterns were part of a European cluster. 
The geographic composition of these molecular clus-
ters ranged from two to 17 countries.
For 73% (n=691) of the European clustered cases, the 
country of origin of the patient was known. In total 73% 
(n=505) of these patients were resident in the country 
of isolation and 27% (n=186) originated from abroad. 
Excluding all clustered cases from Estonia (n=490 for 
which the country of origin was known) because of 
the overrepresentation of samples from Estonia, the 
distribution was 44% (n=89) and 56% (n=112), respec-
tively, for the 201 samples for which country of origin 
was known. 
The percentage of samples assigned to a European 
MDR-/XDR-TB cluster, for the countries which submit-
ted at least 10 isolates to the project database, varied 
from 0 to 87% by country. Clustering on national level 
was also analysed in this study and varied from 0 to 
92% by country (Figure 4).
A number of the VNTR typing patterns (n=465; 22%) did 
not cover all of the 24 loci due to technical problems or 
because these loci were not tested in the participating 
laboratories. In total 60 samples with incomplete VNTR 
patterns were part of molecular clusters (among them 
32 samples of the Beijing genotype): 48% (n=29) of the 
samples with incomplete VNTR patterns were part of 22 
European clusters, while 52% (n=31) of them belonged 
to European clusters which had already been defined 
on the basis of 24-locus VNTR results from at least two 
other samples from two different countries. 
Of all clustered isolates included in the project data-
base, 60% (n=470) were part of one large VNTR typing 
cluster (Figure 3; Table 2). This molecular cluster, com-
prising a VNTR pattern with a Beijing genotype signa-
ture, has so far been detected in 17 EU countries. The 
majority of cases that belonged to this cluster were 
detected in the Baltic States, mainly in Estonia (Figure 
5). Because of the high coverage of reported cases in 
Estonia, 98% for the period 2003 to 2009, the growth 
dynamics of this largest molecular cluster are depicted 
Figure 2
Mycobacterium tuberculosis isolates included in the molecular surveillance project, by year of isolation, 2003–2011 (n=2,055) 
MDR-/XDR-TB: multi- and extensively drug-resistant tuberculosis.
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in Figure 6. In 2009, 72 isolates in the cluster origi-
nated from Estonia; in the following years, this number 
decreased to 42–55 isolates per year.
For a selection of 48 (10%) isolates in the largest 
molecular cluster, isolated in different countries and 
years, we determined the mutations underlying the 
resistance mechanism. All but one of the tested MDR-/
XDR-TB isolates in the VNTR cluster with Beijing gen-
otype revealed the same combination of mutations 
associated with rifampicin and isoniazid resistance: 
rpoB S531L and katG S315T. One exceptional MDR-/
XDR-TB isolate harboured the rpoB H526Y and katG 
S315T mutations. For 39 of these 48 strains, the resist-
ance to fluoroquinolones and the injectable drugs was 
tested phenotypically: 12 were resistant to both, five 
only to fluoroquinolones, 12 only to injectable drugs, 
and 10 showed no resistance.
Characteristics of clustered MDR-/XDR-TB 
cases
Sex and age did not differ between clustered and non-
clustered cases. The overall mean age was 40 years 
(range: 1–88 years). The percentage of VNTR patterns 
who were part of a European cluster was 54% (n=548) 
Figure 3
Size of European clusters of multi- and extensively drug-resistant tuberculosis cases detected in the molecular surveillance 
project, 2003–2011  (n=79 clusters)
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Figure 4
Percentage of cases in European (n=941) and national (n=1,086) clusters of multi- and extensively drug-resistant 
tuberculosis, by country, molecular surveillance project, 2003–2011
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for isolates from male cases and 49% (n=213) for iso-
lates from female cases.  
Forty-four per cent (n=920) of the analysed VNTR pat-
terns of MDR-/XDR-TB isolates were assigned to the 
Beijing genotype with a similarity of at least 74% on 
the basis of 24-locus VNTR typing. For 71% (n=656) of 
the 920 isolates, the Beijing genotype was confirmed 
by RFLP typing and/or spoligotyping and a non-Beijing 
genotype was confirmed for 17% (n=201) of the 1,173 
strains identified as non-Beijing.
In total, 77% (n=726) of the clustered cases were caused 
by Beijing genotype strains with 37 different VNTR pat-
terns (the two largest molecular clusters were caused 
by Beijing genotype strains). Among non-clustered 
cases, 17% (n=194) were caused by Beijing strains 
(p<0.05). The mean age for MDR-/XDR-TB cases caused 
by Beijing genotype strains was not different from that 
of non-Beijing MDR-/XDR-TB cases: 41.9 vs 39.5 years. 
In relation to the sex distribution, the Beijing geno-
type was more often detected in male than in female 
patients: 53% (n=539) vs 47% (n=206). 
The susceptibility of the M. tuberculosis strains to 
second-line drugs was known for 53% (n=1,080) of 
the isolates. Twelve per cent (n=132) of them were 
XDR-TB, and 135 VNTR patterns were found for them. 
There were significantly more men than women among 
XDR-TB patients: 69% (n=91) vs 23% (n=31) (p<0.05). 
XDR-TB was significantly more often detected in 
MDR-TB strains of the Beijing genotype than in MDR-TB 
Table 2
24-locus VNTR pattern of the largest multi- and extensively drug-resistant tuberculosis cluster with a Beijing genotype 
signature detected in the European Union, 2003–2011 (n=470 isolates)
Genome position number 58
0
29
96
80
2
96
0
16
44
31
92
42
4
57
7
21
65
24
01
36
90
41
56
21
63
b
19
55
40
52
15
4
25
31
43
48
20
59
26
87
30
07
23
47
24
61
31
71
Number of tandem repeats 2 7 3 3 3 5 4 4 4 4 3 2 6 5 7 2 5 3 2 1 3 4 2 3
VNTR: variable number of tandem repeat.
Figure 5
Geographical distribution of cases in the largest European multi- and extensively drug-resistant tuberculosis cluster 2003–
2011 (n=470)
BE: Belgium; CZ: Czech Republic; DE: Germany; DK: Denmark; EE: Estonia; ES: Spain; FI: Finland; FR: France; GR: Greece; IE: Ireland; IT: Italy; 
LT: Lithuania; LV: Latvia; NL: the Netherlands; NO: Norway; SE: Sweden; UK: United Kingdom.
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strains of non-Beijing genotypes: 86% (n=116) vs 14% 
(n=19) (p<0.01). In addition, 78% (n=105) of the XDR-TB 
VNTR patterns belonged to eight international clusters; 
six of these clusters were determined as the Beijing 
genotype. 
Discussion
Almost half of the VNTR patterns collected in this 
molecular surveillance study of MDR/XDR M. tubercu-
losis was assigned to international European clusters, 
and 60% of these were part of a single, large European 
cluster. This molecular cluster, associated with the 
spread of a Beijing genotype strain, has so far been 
detected in 17 European countries. It was previously 
described in the EU by RFLP typing and notified for the 
first time in 2003 [1,2]. The RFLP typing results were 
available for 63% (n=125) of the isolates obtained from 
the largest VNTR cluster in 2003 to 2005. This con-
firmed the clustering of these cases on the basis of 
both RFLP and VNTR typing. Overall, the Beijing geno-
type was significantly associated with clustering, and 
therefore with possible (international) transmission 
and spread.
The high proportion of molecular clustering (45%) 
in the EU suggests that MDR-/XDR-TB cases may be 
transmitted and not acquired. The lack of coverage 
and the wide variation in the number and time period 
of collected samples submitted by the participating 
countries, however, reduce the representativeness of 
this observation. Furthermore, a high proportion of the 
European clustered cases (73%) were patients origi-
nating from the country of isolation rather than immi-
grants. Even when excluding all Estonian isolates, the 
percentage was still 44%. This confirms that MDR-/
XDR-TB transmission was taking place and that not all 
detected molecular clusters were a result of human 
migration.
The high percentage of European and national cluster-
ing, especially in Estonia (87% and 92%) and Latvia 
(72% and 66%), indicates that transmission has been 
ongoing in this region for a prolonged period [7], and 
this calls into question the infection control practices 
and the quality of treatment. In contrast, the low per-
centage of clustering in Italy (8%) and Spain (15%) 
indicates that the MDR-TB problem in these regions is 
mainly due to TB imported by immigration from coun-
tries not participating in the project, as suggested ear-
lier [8,9]. In addition, countries with a higher percentage 
of European clustering compared to the percentage of 
national clustering, e.g. the Netherlands (41% vs 23%) 
and Finland (57% vs 19%), are examples of importation 
of MDR-/XDR-TB from European countries and a health 
system that prevents national transmission. 
XDR-TB was detected in 12% (n=132) of the M. tuber-
culosis isolates for which second-line drug suscepti-
bility data was available. This is slightly higher than 
described earlier for the MDR-TB cases examined in 
the period 2006 to 2009 [2]. The Beijing genotype is 
associated with multidrug resistance in many settings 
[10]. In this European surveillance project, the Beijing 
genotype was significantly associated with XDR-TB, in 
contrast to strains of non-Beijing genotypes: respec-
tively 86% (n=116) and 14% (n=19). The association of 
the Beijing genotype with resistance has been studied 
extensively; potential underlying mechanisms include 
a higher mutation frequency of the rpoB gene in strains 
of the Beijing genotype, resulting in a higher ability to 
withstand rifampicin exposure [11]. 
The most important limitation of our study is the poor 
coverage and thus the possible selection bias; the per-
centage of MDR/XDR M. tuberculosis isolates that were 
actually submitted by the participating countries in the 
period from 2003 to 2011 ranged from 0% to more than 
100%. Limited coverage also affected the timeliness 
Figure 6
Multi- and extensively drug-resistant Mycobacterium tuberculosis isolates belonging to the largest European cluster, by year, 
Estonia, 2003–2009 (n=384)
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of delivery of data. Several countries, including a few 
large ones, reported limited data, although it was 
agreed in the project to send real-time typing results. 
The effect of this limitation is a possible underestima-
tion of international transmission of MDR-/XDR-TB in 
the EU. An important implication of our study is that 
especially in western EU countries, the percentage 
of clustered MDR-/XDR-TB cases is low. This implies 
that resistance was either acquired in the patient in 
the country where the strain was isolated, or a conse-
quence of sequential import of unrelated cases from 
endemic regions. 
In contrast, in the eastern EU countries and especially 
the Baltic States, a large proportion of MDR-/XDR-TB 
isolates belonged to molecular clusters. Moreover, 
one large molecular cluster of 470 cases was caused 
by Beijing strains with identical 24-locus VNTR typ-
ing patterns. This implies major and ongoing trans-
mission of an easily transmissible and virulent strain 
or clone. Forty-seven of the 48 tested isolates in the 
largest molecular cluster had the same combination of 
rpoB S531L and katG S315T mutations, associated with 
rifampicin and isoniazid resistance. There is bacterio-
logical and epidemiological data demonstrating that 
these mutations result in the lowest loss of fitness in 
isoniazid- and rifampicin-resistant bacteria [12,13]. 
Resistance to second-line drugs was high variable. The 
largest international cluster may therefore be caused 
by one successful MDR-/XDR-TB strain that is responsi-
ble for many transmissions, with resistance to second-
line drugs developing further in the affected patients. 
Alternatively, we may be observing the spread of 
genetically highly similar strains of the Beijing geno-
type. By whole-genome sequencing, the true percent-
age of similarity can be determined, and this will help 
to answer this question. 
Another important limitation in this study was the lack 
of epidemiological data to confirm chains of human 
transmission. Although the typing data are highly sug-
gestive of spread of successful strains, this still needs 
to be confirmed. 
For this project, we selected VNTR typing as the stand-
ard method. This technique was previously shown to be 
highly reproducible, both within [14] and between lab-
oratories [15]. However, the participants of the ECDC/
RIVM project used a large variation in protocols and 
methodologies and had different levels of experience in 
performing VNTR typing. Therefore, we performed two 
proficiency studies; initial results were disappointing 
regarding both the intra- and inter-laboratory reproduc-
ibility [5]. Although several suggestions for improve-
ments were communicated to participants, this lack in 
quality may still have influenced the results of the cur-
rent study, leading to an underestimation of clustering 
cases. After implementation of several improvements 
in the methodology and a higher degree of standardi-
sation, the second international proficiency study in 
2010 on VNTR typing yielded much better results [16].
In conclusion, large-scale international transmission 
of MDR-/XDR-TB occurs within the EU and demands 
increased surveillance and public health action. The 
M. tuberculosis strains with Beijing genotype are large 
drivers of this international transmission and are asso-
ciated with the emergence and spread of XDR-TB.
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